Novartis AG (NOT) Price & Analysis

Compare

23 Followers

NOT Stock Chart & Stats

€131.44

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€131.44

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€79.74 - €132.08

Previous CloseN/A

Volume24.84K

Average Volume (3M)909.00

Market Cap

€248.87B

Enterprise Value€324.94B

Total Cash (Recent Filing)€11.58B

Total Debt (Recent Filing)€37.01B

Price to Earnings (P/E)20.5

Beta0.32

Next Earnings

Apr 28, 2026

EPS Estimate

1.8

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.70

Shares Outstanding2,112,421,900

10 Day Avg. Volume1,167

30 Day Avg. Volume909

Financial Highlights & Ratios

PEG Ratio0.66

Price to Book (P/B)5.81

Price to Sales (P/S)4.69

P/FCF Ratio14.54

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€125.35

Price Target Upside-4.63% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering14

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Commercial Launch TractionRecent product launches including Pluvicto, Scemblix, and Leqvio have shown early commercial traction, supporting prospects for sustainable revenue growth.

Late-stage Pipeline DepthAnalyst's Buy rating rests on a deep mid-to-late-stage pipeline with multiple programs that could drive future sales and reduce exposure to patent expirations.

Strategic Acquisition AssetsAvidity acquisition adds neuromuscular and other assets that analysts view as significant commercial opportunities and as catalysts for future product launches.

Bears Say

Delayed Clinical ReadoutsDelays in several late-stage development programs have pushed out expected clinical readouts, reducing near-term approval and commercial catalysts.

Guidance And Margin PressureCompany guidance implies weaker profit expectations with margin dilution tied to the acquisition and ongoing loss of exclusivity on certain products.

Sales Shortfalls And AdjustmentsReported sales were impacted by revenue deduction adjustments and channel mix shifts, contributing to missed sales expectations and near-term upside risk.

Novartis AG News

Novartis breaks ground on biomedical research center in San Diego

Novartis (NVS) today broke ground on a new, global Biomedical Research center in San Diego, California. Once operational...

4d ago

NVS

Trump Trade: Argentina says U.S. to cut hundreds of tariffs

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

4d ago

AZN

Novartis price target lowered to CHF 132 from CHF 133 at Citi

Citi analyst Graham Parry lowered the firm’s price target on Novartis (NVS) to CHF 132 from CHF 133...

4d ago

NVS

TrumpRx website using technology from GoodRx, STAT says

President Trump is planning to announce the launch of his TrumpRx website, which uses technology from health care...

5d ago

AZN

BMY

Novartis reports Q4 core EPS $2.03 vs. $1.98 last year

Reports Q4 net sales $13.34B vs. $13.15B last year. Commenting on Q4 2025 results, Vas Narasimhan, CEO of...

6d ago

NVS

Novartis sees FY26 net sales up low single digits vs. last year

Sees FY26 core operating income down low single digits vs. last year. “On December 19, 2025, Novartis (NVS)...

6d ago

NVS

Novartis proposes dividend of CHF 3.70 per share for 2026

07:30 EST Novartis (NVS) proposes dividend of CHF 3.70 per share for 2026 Published first on TheFly –...

6d ago

NVS

Avidity Biosciences announces expected record date for spin-off

Avidity Biosciences (RNA) announced that its board of directors has designated the close of business, Eastern Time, on...

7d ago

NVS

RNA

Novartis initiated with a Buy at Citi

Citi analyst Graham Parry initiated coverage of Novartis (NVS) with a Buy rating and CHF 133 price target...

14d ago

NVS

AI Daily: Nvidia invests $2B in CoreWeave

Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies...

15d ago

LLY

NVS

Looking for Exposure to Johnson & Johnson Stock (JNJ) ahead of Q4 Earnings? Here’s How to Buy Without the Risk

Johnson & Johnson ($JNJ) is set to report its Q4 earnings on January 21. Analysts expect revenue of about $24.16...

22d ago

BMY

IHE

Novartis: Resilient Core Performance and Medium-Term Pipeline Catalysts Support Buy Rating Despite Near-Term Guidance Softness

Morgan Stanley analyst Thibault Boutherin maintained a Buy rating on Novartis AG today and set a price target...

6d ago

NVS

Buy Rating on Novartis: Near-Term Guidance Headwinds Outweighed by Resilient Fundamentals, Advancing Pipeline, and Supportive Valuation

Sachin Jain, an analyst from Bank of America Securities, maintained the Buy rating on Novartis AG. The associated...

6d ago

NVS

Novartis: Resilient Core Earnings, Conservative Guidance and Robust Pipeline Support Buy Rating and EPS Upside to 2030

Citi analyst Graham Parry maintained a Buy rating on Novartis AG today and set a price target of...

6d ago

NVS

NOT FAQ

What was Novartis AG’s price range in the past 12 months?

Novartis AG lowest stock price was €79.74 and its highest was €132.08 in the past 12 months.

What is Novartis AG’s market cap?

Novartis AG’s market cap is €248.87B.

When is Novartis AG’s upcoming earnings report date?

Novartis AG’s upcoming earnings report date is Apr 28, 2026 which is in 77 days.

How were Novartis AG’s earnings last quarter?

Novartis AG released its earnings results on Feb 04, 2026. The company reported €1.705 earnings per share for the quarter, beating the consensus estimate of €1.67 by €0.034.

Is Novartis AG overvalued?

According to Wall Street analysts Novartis AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Novartis AG pay dividends?

Novartis AG does not currently pay dividends.

What is Novartis AG’s EPS estimate?

Novartis AG’s EPS estimate is 1.8.

How many shares outstanding does Novartis AG have?

Novartis AG has 2,112,421,900 shares outstanding.

What happened to Novartis AG’s price movement after its last earnings report?

Novartis AG reported an EPS of €1.705 in its last earnings report, beating expectations of €1.67. Following the earnings report the stock price went up 1.336%.

Which hedge fund is a major shareholder of Novartis AG?

Currently, no hedge funds are holding shares in DE:NOT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG (NOT) Earnings & Revenues

Historic Earnings Reports

NOT Stock 12 Month Forecast

Average Price Target

€125.35

▼(-4.63% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"75":"€75","144":"€144","92.25":"€92.3","109.5":"€109.5","126.75":"€126.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":143.883696,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€143.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125.35322,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€125.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100.282576,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€100.28</span>\n  </div></div>","useHTML":true}}],"tickPositions":[75,92.25,109.5,126.75,144],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,127.7,128.9448996923077,130.18979938461538,131.43469907692307,132.67959876923078,133.92449846153846,135.16939815384615,136.41429784615383,137.65919753846154,138.90409723076922,140.1489969230769,141.3938966153846,142.6387963076923,{"y":143.883696,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,127.7,127.51947846153847,127.33895692307692,127.15843538461539,126.97791384615384,126.7973923076923,126.61687076923077,126.43634923076922,126.25582769230769,126.07530615384616,125.89478461538461,125.71426307692307,125.53374153846153,{"y":125.35322,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,127.7,125.59096738461538,123.48193476923078,121.37290215384616,119.26386953846153,117.15483692307693,115.04580430769231,112.9367716923077,110.82773907692308,108.71870646153846,106.60967384615385,104.50064123076923,102.39160861538463,{"y":100.282576,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":76.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.44,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.02,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.24,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >